



## **Mersana Therapeutics to Present at Wedbush PacGrow Healthcare Conference**

August 9, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 9, 2017-- [Mersana Therapeutics, Inc.](http://www.businesswire.com/news/home/20170809005756/en/) (NASDAQ:MRSN), today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the Wedbush PacGrow Healthcare Conference in New York City on Wednesday, August 16, 2017, from 10:20-10:50am EDT.

### **About Mersana Therapeutics**

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's lead product candidate, XMT-1522, is in Phase I clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company expects that its second product candidate, XMT-1536, will enter clinical trials in early 2018. In addition, multiple partners are using Mersana's leading platform to advance their ADC pipelines.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170809005756/en/>

Source: Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc.

#### **Media Contact**

Paul Kidwell, 617-680-1088

[paulkidwell@comcast.net](mailto:paulkidwell@comcast.net)

or

#### **Investors Contact**

Stern Investor Relations, Inc.

Christina Tartaglia, 212-362-1200

[Christina@sternir.com](mailto:Christina@sternir.com)